Vor Biopharma Statistics
Total Valuation
Vor Biopharma has a market cap or net worth of $1.08 billion. The enterprise value is $595.13 million.
| Market Cap | 1.08B |
| Enterprise Value | 595.13M |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vor Biopharma has 54.19 million shares outstanding. The number of shares has increased by 359.89% in one year.
| Current Share Class | 54.19M |
| Shares Outstanding | 54.19M |
| Shares Change (YoY) | +359.89% |
| Shares Change (QoQ) | +111.92% |
| Owned by Insiders (%) | 2.19% |
| Owned by Institutions (%) | 46.87% |
| Float | 35.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 31.15
| Current Ratio | 31.15 |
| Quick Ratio | 30.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -69.76% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -76.12% |
| Weighted Average Cost of Capital (WACC) | 13.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$11.62M |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.55% in the last 52 weeks. The beta is 1.70, so Vor Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.70 |
| 52-Week Price Change | -54.55% |
| 50-Day Moving Average | 16.35 |
| 200-Day Moving Average | 15.69 |
| Relative Strength Index (RSI) | 60.89 |
| Average Volume (20 Days) | 1,308,312 |
Short Selling Information
The latest short interest is 7.29 million, so 13.45% of the outstanding shares have been sold short.
| Short Interest | 7.29M |
| Short Previous Month | 7.74M |
| Short % of Shares Out | 13.45% |
| Short % of Float | 20.44% |
| Short Ratio (days to cover) | 3.86 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -343.81M |
| Pretax Income | -883.08M |
| Net Income | -883.08M |
| EBITDA | -367.52M |
| EBIT | -373.51M |
| Earnings Per Share (EPS) | -$46.32 |
Balance Sheet
The company has $491.53 million in cash and $2.94 million in debt, with a net cash position of $488.59 million or $9.02 per share.
| Cash & Cash Equivalents | 491.53M |
| Total Debt | 2.94M |
| Net Cash | 488.59M |
| Net Cash Per Share | $9.02 |
| Equity (Book Value) | -150.42M |
| Book Value Per Share | -2.78 |
| Working Capital | 484.70M |
Cash Flow
In the last 12 months, operating cash flow was -$149.89 million and capital expenditures -$758,000, giving a free cash flow of -$150.65 million.
| Operating Cash Flow | -149.89M |
| Capital Expenditures | -758,000 |
| Depreciation & Amortization | 2.09M |
| Net Borrowing | n/a |
| Free Cash Flow | -150.65M |
| FCF Per Share | -$2.78 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vor Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -359.89% |
| Shareholder Yield | -359.89% |
| Earnings Yield | -81.49% |
| FCF Yield | -13.90% |
Analyst Forecast
The average price target for Vor Biopharma is $37.88, which is 89.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $37.88 |
| Price Target Difference | 89.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 19, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 19, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |